A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer
Kenzo Soejima(Keio University), Tomoko Betsuyaku(Tokyo Medical University), Sohei Nakayama(Beth Israel Deaconess Medical Center), Makoto Nishino(Keio University), Hideo Watanabe(St. Catherine University), Tetsuo Tani(Keio University), Keiko Ohgino(Keio University), Satoshi Yoda(Harvard University), Aoi Kuroda(Keio University), Hideki Terai(Kitasato Institute Hospital), Kota Ishioka(Keio University), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Morio Nakamura(Saiseikai Central Hospital), Daisuke Arai(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Michie Nakatani(Eiju General Hospital), Ichiro Kawada(Keio University), Katsuhiko Naoki(Broad Institute), Ryosuke Satomi(Tokyo Medical Center), Takashi Sato(Kitasato University), Sinnosuke Ikemura(Keio University)
Cited by 7
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>Fusobacterium nucleatum</i>and T Cells in Colorectal Carcinoma
|JAMA Oncology|2015|660
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565